> Shares in Ascendis Pharma soared after the Danish drug developer showed its once-weekly growth hormone outperformed Pfizer’s Genotropin in a phase 3 trial. Ascendis plans to file for FDA approval of the drug in the first half of next year. Statement
> Intarcia Therapeutics exercised its option to license ND016 from Numab Therapeutics. Switzerland's Numab is in line to receive up to CHF 70 million ($70 million) in return for the tri-specific autoimmune drug. Release
> Nanobiotix received the second, €14 million tranche of funding from the European Investment Bank. The payment was triggered by the progress of cancer treatment NBTXR3. Statement
> Transgene is set to move neoantigen therapeutic vaccine TG4050 into the clinic this year under its collaboration with NEC. The partners will co-fund two studies of the candidate. Release
> Verona Pharma presented interim data on its dry powder inhaler formulation of ensifentrine in moderate-to-severe chronic obstructive pulmonary disease. The trial linked single doses of the drug to statistically significant improvements in lung function. Statement
> NovaGo Therapeutics closed a CHF 10 million series A round. The Swiss biotech will use the money to move a cerebral stroke candidate toward the clinic. Release